Anti HL-A2 Inhibitor in Normal Human Serum

Rood, J.J. van; Leeuwen, A. van; Santen, M. C. T. Van

doi:10.1038/226366a0

Cited by 208 publications

(74 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,2 Beside being expressed on most nucleated cells, both b2-microglobulin associated and free HLA-I heavy chains have been detected in serum. [2][3][4][5] More recently, it has been shown that the serum level of these soluble molecules is significantly increased in patients with an activation of their immune system, such as during allograft rejection, autoimmune diseases or viral infections. 1,6 Because of the statistical significant association with clinical parameters, the amount of soluble human leukocyte antigens (sHLA)-I antigens has been proposed as a useful marker to predict the evolution of chronic viral infections and the clinical course of allografts.…”

Section: Introductionmentioning

confidence: 99%

In vivo apoptosis of CD8+ lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-I and Fas ligand

et al. 2006

View full text Add to dashboard Cite

In this study, we show that high serum levels of soluble human leukocyte antigens (HLA) class I molecules (sHLA-I, range: 0.7-1.7 lg/ml) and soluble Fas ligand (FasL, range: 0.4-1.9 ng/ml) are detected in patients with acute myeloid leukemia (AML) at diagnosis, compared with healthy donors (HD) (sHLA-I, range: 0.1-0.6 lg/ml; sFasL, range: 0.1-0.4 ng/ml). Patients' sera were able to induce transcription and secretion of FasL in CD8 þ T cells, followed by apoptosis in vitro; this apoptosis was inhibited by anti-HLA-I-specific monoclonal antibodies, suggesting that sHLA-I is responsible for cell death. These findings closely relate to the in vivo upregulation of FasL transcription observed in peripheral blood (PB) lymphocytes from AML patients; in the same cells, mRNA for the antiapoptotic proteins Bcl-2 and Bcl-x L was downregulated. Interestingly, caspase-8 and caspase-3, both downstream mediators of death receptorinduced apoptosis, were activated in CD8 þ cells of AML patients; one-third of these cells were already apoptotic in vivo, at variance with lymphocytes of HD. These data strongly suggest that in AML, increased levels of sHLA-I molecules may contribute to the elimination of potentially anti-tumor effector cells through a FasL/Fas interaction.

show abstract

Section: Introductionmentioning

confidence: 99%

In vivo apoptosis of CD8+ lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-I and Fas ligand

et al. 2006

View full text Add to dashboard Cite

show abstract

“…The class Ib molecules include the gene products of HLA-E, HLA-F, and HLA-G loci and are characterized by a restricted tissue distribution and by limited polymorphism. Besides being expressed on nucleated cells, classical and nonclassical HLA class I molecules are present in serum in soluble form (sHLA-I) [1,2]. The serum level of sHLA-I molecules is significantly increased in a variety of physiological and pathological conditions such as pregnancy, acute rejection episodes following organ allografts, acute graft-versus-host-disease (GVHD) following bone marrow transplantation, autoimmune diseases, viral infections, and malignant melanoma [3,4,5,6].…”

mentioning

confidence: 99%

Soluble HLA Class I Molecules/CD8 Ligation Trigger Apoptosis of CD8⁺Cells by Fas/Fas-Ligand Interaction

Puppo¹,

Contini²,

Ghio³

et al. 2002

The Scientific World JOURNAL

View full text Add to dashboard Cite

“…Soluble MHC (sMHC) molecules were first shown to exist in healthy humans more than 40 years ago when Charlton and Zmijewski [17] and van Rood et al [18] independently found that serum MHC class I antigens were able to block anti-HLA-A2 antibodies. About twenty years later, these sMHC molecules were implicated in disease after they were shown to inhibit allospecific T cell responses [19].…”

Section: Mhc-ig Fusion Proteinsmentioning

confidence: 99%

MHC-Ig Dimers: The next Frontier in Transplantation Immunology

Wigina

Jeza

2015

Int Jour of Biomed Res

View full text Add to dashboard Cite

Organ transplantation offers hope to a variety of patients with terminal functioning organs and tissues. This is currently made possible by administration of general immunosuppressive drugs. To date, inducing tolerance to allografts has become the holy grail of every transplantation immunologist. In effect, there has been a great deal of research aiming to come up with alternative therapeutic mechanisms that would allow one to do away with or reduce the amount of general immunosuppressive drugs used either at the induction, maintenance, or both phases. It has been shown in recent years that MHC-Ig dimers can induce suppression of alloresponsive T cells in a donor specific fashion. Consequently, MHC-Ig fusion proteins are currently forming the next field for exploitation which is great progress in transplantation immunology since the discovery of the first immunosuppressive drugs in terms of inducing tolerance to transplanted organs and tissues. This review aims to discuss this progress.

show abstract

Anti HL-A2 Inhibitor in Normal Human Serum

Cited by 208 publications

References 2 publications

In vivo apoptosis of CD8+ lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-I and Fas ligand

In vivo apoptosis of CD8+ lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-I and Fas ligand

Soluble HLA Class I Molecules/CD8 Ligation Trigger Apoptosis of CD8⁺Cells by Fas/Fas-Ligand Interaction

MHC-Ig Dimers: The next Frontier in Transplantation Immunology

Contact Info

Product

Resources

About

Anti HL-A2 Inhibitor in Normal Human Serum

Cited by 208 publications

References 2 publications

In vivo apoptosis of CD8+ lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-I and Fas ligand

In vivo apoptosis of CD8+ lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-I and Fas ligand

Soluble HLA Class I Molecules/CD8 Ligation Trigger Apoptosis of CD8+Cells by Fas/Fas-Ligand Interaction

MHC-Ig Dimers: The next Frontier in Transplantation Immunology

Contact Info

Product

Resources

About

Soluble HLA Class I Molecules/CD8 Ligation Trigger Apoptosis of CD8⁺Cells by Fas/Fas-Ligand Interaction